JMPWA
ARQT icon

JP Morgan Private Wealth Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,058
Closed -$111K – 1495
2023
Q1 		$111K Buy
+10,058
New +$146K ﹤0.01% 1892

Other funds holding ARQT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

JP Morgan Private Wealth Advisors's ARQT Position: Q2 2023 in Review

JP Morgan Private Wealth Advisors sold out of Arcutis Biotherapeutics (ARQT) in Q2 2023, closing a stake of 10,058 shares — an estimated $111K sold.

JP Morgan Private Wealth Advisors first reported a position in ARQT in Q1 2023 and held it in 1 quarter. The position peaked at $111K in Q1 2023. 136 funds tracked by Wall St. Rank hold ARQT as of Q2 2023.

  • JP Morgan Private Wealth Advisors reported no remaining Arcutis Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • JP Morgan Private Wealth Advisors sold 10,058 Arcutis Biotherapeutics shares in Q2 2023, an estimated $111K.
  • JP Morgan Private Wealth Advisors first reported a position in Arcutis Biotherapeutics in Q1 2023 and held it in 1 quarter.
  • JP Morgan Private Wealth Advisors's Arcutis Biotherapeutics position peaked at $111K in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2023.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.